1-(6-methoxypyridin-2-yl)-N-methylmethanamine | 1060806-94-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 1-(6-methoxypyridin-2-yl)-N-methylmethanamine
• 英文别名: [(6-Methoxypyridin-2-yl)methyl](methyl)amine
• CAS: 1060806-94-1
• 化学式: C₈H₁₂N₂O
• mdl: MFCD13188748
• 分子量: 152.196
• InChiKey: ZCDSYDMWOVSOBD-UHFFFAOYSA-N

物化性质

• 沸点：
  209.9±25.0 °C(Predicted)
• 密度：
  1.026±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.375
• 拓扑面积：
  34.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(6-methoxypyridin-2-yl)-N-methylmethanamine 在 三甲基氯硅烷 、 sodium iodide 作用下， 以 乙腈 为溶剂， 反应 3.5h， 生成 6-((methylamino)methyl)pyridin-2(1H)-one
  参考文献：
  名称：

  [EN] NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS
  [FR] NOUVEAUX AGONISTES DE RÉCEPTEURS ADRÉNERGIQUES BÊTA 3 DÉRIVÉS DE PYRROLIDINE

  摘要：

  本发明提供了式（I）的化合物，其药物组成物以及使用该药物组成物在治疗或预防由β3-肾上腺素受体激活介导的疾病的方法。

  公开号：

  WO2015050798A1
• 作为产物：
  描述：

  6-甲氧基吡啶-2-甲醛 、 甲胺 在 溶剂黄146 、 三乙酰氧基硼氢化钠 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 14.0h， 以8 g的产率得到1-(6-methoxypyridin-2-yl)-N-methylmethanamine
  参考文献：
  名称：

  [EN] NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS
  [FR] NOUVEAUX AGONISTES DE RÉCEPTEURS ADRÉNERGIQUES BÊTA 3 DÉRIVÉS DE PYRROLIDINE

  摘要：

  本发明提供了式（I）的化合物，其药物组成物以及使用该药物组成物在治疗或预防由β3-肾上腺素受体激活介导的疾病的方法。

  公开号：

  WO2015050798A1

文献信息

• Cyclic compounds
  申请人：Yamada Koichiro

  公开号：US20080027037A1

  公开（公告）日：2008-01-31

  1. A cyclic compound of the formula (I) or a pharmacologically acceptable salt thereof, wherein X is ═CH— or ═N—, Y is —NH—, —NR 4 —, —S—, —O—, —CH═N—, —N═CH—, —N═N—, —CH═CH—, etc., R 1 is a lower alkoxy group, an amino group, a heterocyclic ring containing N atom(s), or a hydroxy group substituted by a heterocyclic ring containing N atom(s) (each of which is optionally substituted), R 2 is a lower alkylamino group which is optionally substituted by an aryl group, a lower alkoxy group which is optionally substituted by an aryl group, a lower alkoxy group substituted by an aromatic heterocyclic ring containing N atom(s), R 3 is an aryl group, a heterocyclic ring containing N atom(s), a lower alkyl group, a lower alkoxy group, a cyclo lower alkoxy group, a hydroxy group substituted by a heterocyclic ring containing N atom(s), or an amino group (each of which is optionally substituted), and R 3 and a substituent in Y may be combined to form a lactone ring. The compound of the present invention has excellent selective PDE V inhibitory activity and therefore, is useful as a therapeutic or prophylactic drug for treating various diseases due to functional disorders on cGMP-signaling.

  公式（I）的环状化合物或其药学上可接受的盐，其中X为═CH—或═N—，Y为—NH—、—NR4—、—S—、—O—、—CH═N—、—N═CH—、—N═N—、—CH═CH—等，R1为较低的烷氧基、氨基、含N原子的杂环环或含N原子的杂环环取代的羟基（每个都可选地取代），R2为较低的烷基氨基，可选地取代芳基基团、可选地取代的较低的烷氧基、取代芳香族含N原子的杂环环的较低的烷氧基，R3为芳基基团、含N原子的杂环环、较低的烷基、较低的烷氧基、环状较低的烷氧基、含N原子的杂环环取代的羟基或氨基（每个都可选地取代），R3和Y中的取代基可结合形成内酯环。本发明的化合物具有优异的选择性PDE V抑制活性，因此，可用作治疗或预防因cGMP信号传导功能障碍引起的各种疾病的药物。
• 2,4,6-TRIAMINO-1,3,5-TRIAZINE DERIVATIVE
  申请人：Kubota Hideki

  公开号：US20080227785A1

  公开（公告）日：2008-09-18

  This invention relates to an anti-dementia agent which uses a BEC 1 potassium channel inhibitor as the active ingredient. It was proved that the BEC 1 potassium channel inhibitor has an action to improve learning disorder and is useful as a preventive or therapeutic agent for diseases, preferably dementia, in which the BEC 1 potassium channel is considered to be concerned. Illustratively, it was confirmed by an in vivo test that the BEC 1 potassium channel inhibitor has an action to improve learning disorder. Also, it was found that a compound having 2,4,6-triamino-1,3,5-triazine has a BEC 1 potassium channel inhibitory action.

  本发明涉及一种以BEC 1钾离子通道抑制剂作为活性成分的抗痴呆剂。已经证明，BEC 1钾离子通道抑制剂具有改善学习障碍的作用，并且作为预防或治疗剂是有用的，尤其是对于BEC 1钾离子通道与之相关的疾病，如痴呆症。例如，通过体内试验证实，BEC 1钾离子通道抑制剂具有改善学习障碍的作用。此外，还发现具有2,4,6-三氨基-1,3,5-三嗪的化合物具有BEC 1钾离子通道抑制作用。
• HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES
  申请人：Bunnage Mark Edward

  公开号：US20130196952A1

  公开（公告）日：2013-08-01

  The invention relates to compounds of Formula (1) and to processes for the preparation of intermediates used in the preparation of compositions containing and the uses of such derivatives. The compounds according to the present invention are useful in numerous diseases in which ALK protein is involved or in which inhibition of ALK activity may induce benefit, especially for the treatment of cancer mediated by a mutated EML4-ALK fusion protein.

  本发明涉及式（1）的化合物，以及用于制备含有这些衍生物的组合物的中间体的制备过程和使用。根据本发明的化合物在许多与ALK蛋白有关或抑制ALK活性可能产生益处的疾病中非常有用，特别是用于治疗由突变的EML4-ALK融合蛋白介导的癌症。
• NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS
  申请人：Barr Kenneth Jay

  公开号：US20160235727A1

  公开（公告）日：2016-08-18

  The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of us ing the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor.

  本发明提供了式（I）的化合物、其制药组合物以及使用它们治疗或预防由β3-肾上腺素受体激活介导的疾病的方法。
• CYCLIC COMPOUNDS
  申请人：TANABE SEIYAKU CO., LTD.

  公开号：EP1277741A1

  公开（公告）日：2003-01-22

  1. A cyclic compound of the formula (I) or a pharmacologically acceptable salt thereof,    wherein X is =CH-or=N-, Y is-NH-, -NR4-, -S-, - O-, -CH=N-, -N=CH-, -N=N-, -CH=CH-, etc., R1 is a lower alkoxy group, an amino group, a heterocyclic ring containing N atom(s), or a hydroxy group substituted by a heterocyclic ring containing N atom(s) (each of which is optionally substituted), R2 is a lower alkylamino group which is optionally substituted by an aryl group, a lower alkoxy group which is optionally substituted by an aryl group, a lower alkoxy group substituted by an aromatic heterocyclic ring containing N atom(s), R3 is an aryl group, a heterocyclic ring containing N atom(s), a lower alkyl group, a lower alkoxy group, a cyclo lower alkoxy group, a hydroxy group substituted by a heterocyclic ring containing N atom(s), or an amino group (each of which is optionally substituted), and R3 and a substituent in Y may be combined to form a lactone ring.    The compound of the present invention has excellent selective PDE V inhibitory activity and therefore, is useful as a therapeutic or prophylactic drug for treating various diseases due to functional disorders on cGMP-signaling.

  1.式（I）的环状化合物或其药理学上可接受的盐、 其中 X 是 =CH-or=N-, Y 是-NH-、-NR4-、-S-、-O-、-CH=N-、-N=CH-、-N=N-、-CH=CH-等、R1 是低级烷氧基、氨基、含 N 原子的杂环或被含 N 原子的杂环取代的羟基（其中每一个都可选择被取代）， R2 是低级烷基氨基，可选择被芳基取代，低级烷氧基，可选择被芳基取代、R3 是芳基、含 N 原子的杂环、低级烷基、低级烷氧基、环低级烷氧基、被含 N 原子的杂环取代的羟基或氨基（其中每个基团都可选择被取代），R3 和 Y 中的一个取代基可结合形成一个内酯环。 本发明的化合物具有优异的选择性 PDE V 抑制活性，因此可用作治疗或预防药物，用于治疗因 cGMP 信号转导功能紊乱而引起的各种疾病。